Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1

Cell Cycle

Volumn 9, Issue 13, 2010, Pages 2502-2507

  Pires, Isabel M ^a   Bencokova, Zuzana ^a   McGurk, Chris ^a   Hammond, Ester M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Chk1; Hypoxia; Reoxygenation; Replication restart; TLK1

Indexed keywords

CHECKPOINT KINASE 1; PROTEIN KINASE; PROTEIN P53; REPLICATION FACTOR A; SMALL INTERFERING RNA; TOUSLED LIKE KINASE 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; DNA DAMAGE; HUMAN; HYPOXIA; PROTEIN PHOSPHORYLATION; REOXYGENATION; REVIEW;

EID: 77955449974     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.13.12059     Document Type: Review

References (48)

1. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56:941-3.
2. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285-9.
3. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999; 59:4525-8. (Pubitemid 29428951)
4. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and Radiation Response in Human Tumors. Semin Radiat Oncol 1996; 6:3-9. (Pubitemid 26029370)
5. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28:36-41.
6. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic and molecular aspects. J Natl Cancer Inst 2001; 93:266-76. (Pubitemid 32219813)
7. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002; 1:453-8.
8. Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol 2007; 435:297-321.
9. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408-16.
10. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4:437-47.
11. Cardenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, Dewhirst MW. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res 2008; 68:5812-9.
12. Hammond EM, Kaufmann MR, Giaccia AJ. Oxygen sensing and the DNA-damage response. Current Opinion in Cell Biology 2007; 19:680-4.
13. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88-91. (Pubitemid 26008141)
14. Papandreou I, Krishna C, Kaper F, Cai D, Giaccia AJ, Denko NC. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res 2005; 65:3171-8. (Pubitemid 40524598)
15. Hammond EM, Green SL, Giaccia AJ. Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest. Mutat Res 2003; 532:205-13.
16. Hammond EM, Giaccia AJ. The role of ATM and ATR in the cellular response to hypoxia and reoxygenation. DNA Repair (Amst) 2004; 3:1117-22.
17. Pires IM, Bencokova Z, Milani M, Folkes LK, Li JL, Stratford MR, et al. Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability. Cancer Res 2010 70:925-35.
18. Probst H, Schiffer H, Gekeler V, Scheffler K. Oxygen dependent regulation of mammalian ribonucleotide reductase in vivo and possible significance for replicon initiation. Biochem Biophys Res Commun 1989; 163:334-40. (Pubitemid 19227310)
19. Blow JJ, Dutta A. Preventing re-replication of chromosomal DNA. Nat Rev Mol Cell Biol 2005; 6:476-86.
20. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8:180-92.
21. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, et al. Hypoxia-induced downregulation of BRCA1 expression by E2Fs. Cancer Res 2005; 65:11597-604. (Pubitemid 41821719)
22. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, et al. Hypoxia downregulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 2005; 76:168-76. (Pubitemid 41725444)
23. Huang LE, Bindra RS, Glazer PM, Harris AL. Hypoxia-induced genetic instability - a calculated mechanism underlying tumor progression. J Mol Med 2007; 85:139-48.
24. Koshiji M, To KK, Hammer S, Kumamoto K, Harris AL, Modrich P, et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 2005; 17:793-803. (Pubitemid 40386941)
25. Lara PC, Lloret M, Clavo B, Apolinario RM, Bordon E, Rey A, et al. Hypoxia downregulates Ku70/80 expression in cervical carcinoma tumors. Radiother Oncol 2008; 89:222-6.
26. Bindra RS, Crosby ME, Glazer PM. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 2007; 26:249-60.
27. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009; 69:1221-9.
28. Koritzinsky M, Magagnin MG, van den Beucken T, Seigneuric R, Savelkouls K, Dostie J, et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J 2006; 25:1114-25. (Pubitemid 43372124)
29. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008; 68:605-14. (Pubitemid 351380090)
30. Freiberg RA, Hammond EM, Dorie MJ, Welford SM, Giaccia AJ. DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response. Mol Cell Biol 2006; 26:1598-609.
31. Junttila MR, Evan GI. p53 - a Jack of all trades but master of none. Nat Rev Cancer 2009; 9:821-9.
32. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421-9. (Pubitemid 38340288)
33. Hammond EM, Dorie MJ, Giaccia AJ. Inhibition of ATR Leads to Increased Sensitivity to Hypoxia/Reoxygenation. Cancer Res 2004; 64:6556-62.
34. Sillje HH, Takahashi K, Tanaka K, Van Houwe G, Nigg EA. Mammalian homologues of the plant Tousled gene code for cell cycle-regulated kinases with maximal activities linked to ongoing DNA replication. EMBO J 1999; 18:5691-702. (Pubitemid 29486387)
35. Groth A, Lukas J, Nigg EA, Sillje HH, Wernstedt C, Bartek J, et al. Human Tousled like kinases are targeted by an ATM- and Chk1-dependent DNA damage checkpoint. EMBO J 2003; 22:1676-87. (Pubitemid 36417415)
36. Krause DR, Jonnalagadda JC, Gatei MH, Sillje HH, Zhou BB, Nigg EA, et al. Suppression of Tousled-like kinase activity after DNA damage or replication block requires ATM, NBS1 and Chk1. Oncogene 2003; 22:5927-37.
37. De Benedetti A. Tousled kinase TLK1B counteracts the effect of Asf1 in inhibition of histone H3-H4 tetramer formation. BMC Res Notes 2009; 2:128.
38. Kodym R, Henockl C, Furweger C. Identification of the human DEAD-box protein p68 as a substrate of Tlk1. Biochem Biophys Res Commun 2005; 333:411-7. (Pubitemid 40848306)
39. Sillje HH, Nigg EA. Identification of human Asf1 chromatin assembly factors as substrates of Tousled-like kinases. Curr Biol 2001; 11:1068-73.
40. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003; 300:1542-8. (Pubitemid 36682880)
41. Sorensen CS, Syljuasen RG, Falck J, Schroeder T, Ronnstrand L, Khanna KK, et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003; 3:247-58. (Pubitemid 37443880)
42. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets and DNA breakage. Mol Cell Biol 2005; 25:3553-62. (Pubitemid 40559562)
43. Syljuasen RG, Sorensen CS, Nylandsted J, Lukas C, Lukas J, Bartek J. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res 2004; 64:9035-40. (Pubitemid 39665514)
44. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, et al. The cell cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7:195-201.
45. Gibson SL, Bindra RS, Glazer PM. Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. Cancer Res 2005; 65:10734-41.
46. Hammond EM, Freiberg RA, Giaccia AJ. The roles of Chk1 and Chk2 in hypoxia and reoxygenation. Cancer Lett 2005.
47. Janetka JW, Ashwell S. Checkpoint kinase inhibitors: a review of the patent literature. Expert Opin Ther Pat 2009; 19:165-97.
48. Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, Caldecott KW. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 2006; 26:3319-26.